ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
  • 鵥Tҩҩÿ

    ʲôҩڻԶǡߡþˣϵͳܻPD-L1Ŀ壬dz֮Ϊ塱һҩԭ򡣻пϵͳ׷ɱУ֮صҪͻ䣬JAK2ͦ2MG»ҩ鵥Tecentriqҩˣô죿1. ٴμ⣬ԭΪJAK2ͻ䣬ʵѾоJAK2Ƽҩ֮ͿЧҩˣΪˡ塱ԿǻɻûвߵPD-1ҩ2.

  • TҩϵɼٰӳPFS

    201938չŮڵ죬ʳƷҩ֣FDA׼˰鵥TECENTRIQGenentech Inc.ɼףPaclitaxel protein-boundƳ˻޷гľֲڻתٰtriple negative breast cancerTNBC鵥һֵ¡壬ϸϸϱPD-L1׽ϣPD-1B7.1໥áͨPD-L1TECENTRIQԼTϸʹЩϸܹɿȥϸ鵥ɼ׽

  • ΰ߿ʹð鵥ЧǶ٣

    20161018FDA׼쵥ڲ໯ҩ(EGFRALK԰ҩ)תԷСϸΰߵơЧʣIIIOAKIIPOPLARоĽоOAKʾۻߵPD-L1״̬Σ״ͷ״Сϸΰ쵥ƶԱȶɼƵĻӳ4.2(13.8 vs 9.6)ʹãÿξע1200ˣ״60ӵעܣ30ɣ3һΣֱչ򲻿ɽܵĶԡ2018126FDA׼쵥ϱͻתԷ״EGFRA

  • 鵥Ӧٰ֢Чô

    201938FDA׼쵥ϰ׵-ɼPD-L1ԡתٰһơIIIIMpassion130оݣо쵥ϰ׵-ɼ׵ɼҩȣʹ񻯻ķŽ40%ӳ޽չ(7.4 vs.4.8) 鵥ʹãÿ28һڣ115ʩãÿξע840mg״60ӵעܣ30;1,815ע׵-ɼֱչ򲻿ɽܵĶԡ鵥ɼ׽ϵӦ

  • 鵥Ӧ֢÷鵥˵顿

    鵥(Atezolizumab)һֵ¡壬ɰPD-L1ס쵥ϸϸϱPD-L1ϣPD-1B7.1໥áͨPD-L1ԼTϸϸϵİ쵥ƷΪTecentriqֳTҩǵһеPD-L1Ƽ(2016518ջFDA׼ת/·Ƥ)ֹĿǰ쵥ڷΰٰIJͬӦ֢ƣҲڶнٴоҩƷƣ鵥(쵥Atezolizumab)ƷƣTecentriq(Tҩ)

  • 鵥(Atezolizumab)ע˵ÿҽ

    鵥(Atezolizumab)һֵ¡壬ɰPD-L1ס쵥ϸϸϱPD-L1ϣPD-1B7.1໥áͨPD-L1ԼTϸϸϵİ쵥ƷΪTecentriqֳTҩǵһеPD-L1Ƽ(2016518ջFDA׼ת/·Ƥ)ֹĿǰ쵥ڷΰٰIJͬӦ֢ƣҲڶнٴоʹTҩľע(1)صķףжȷӦӦͣҩضȻΣ

  • 鵥TҩǰƹתԷСϸΰЧôÿ

    ٴݡOAKNCT02008227)һġ(1:1)űǩоΪֲڻתԷСϸΰߣЩߵIJںڼ֮нչ鰴ϸ(IC) PD-L1ǰƷ(1 VS 2)֯ѧ(״ϸ VS ״ϸ)зֲ㡣Ϊ飬һܰ鵥1200 mgÿ3ܾעһΣֱֲܵĶԷӦӰѧչٴչһɼ75 mg/m2ÿ3ܾעһΣֱֲܵĶԷӦ򼲲չҪЧָΪǰ850

  • 㷺Сϸΰҩ鵥ٴЧΣ

    2019318գ FDA׼鵥Ͽвڹ㷺СϸΰSCLCһơСϸΰΪСϸΰ͹㷺СϸΰڶΪһǻܱһҰڣ㷺ΪԽһǻҰǻİҺѪתơٴݡIMpower133 (NCT02763579)(1:1)ġ˫äοУо˰鵥Ͽвն403㷺СϸΰES-SCLCߵЧ黼֮ǰûнܹ㷺ڼڻƣECOGΪ01

  • 鵥(TecentriqTҩ)ʺ໼߷ãÿ

    ЩʺϷð鵥(TecentriqAtezolizumab)Tҩ?1.ֲڻת·Ƥ鵥(atezolizumab)ھֲڻת·ƤߵƣϺ˳ĻƣPD-L1(FDA׼IJȷPD-L1Ⱦɫϸ[IC]ġ5%);PD-L1״̬ΣκκƵʸ;κκڼ֮󣬻¸Ƶ12ڣչ;ָӦʺͷӦ־ڼ׼»׼ָij׼ȡȷеٴ

  • 鵥(Atezolizumab)ãһƳҪ೤ʱ䣿

    鵥ҩ̼ϵͳڵٺ֯ػΣIJ֢κ֢״ϵҽҪԴ(1) β:(ףβ֢)µĻ񻯵Ŀԣ̴٣ѻʹ(2) :(ף෢)Ƥ۾ƣҺʰɫʹѪ˱ףصĶĺŻ¡(3) к/:(᳦ף֢)ʹкΣճҺѪҺڰ㣬աкԲͬζŲͬĶ(4) 쳣߷ӦӰ

  • ľƶ෢ԹߵЧȫԳڣÿҽ

    ڴľ1/2ٴоУͨԸθߵоûлܼо16mg/kgľȡ36%ЧʣORRо˴ľҪһƵĶ෢ԹߵЧЩ߰1Ʒҩ֮ǰܹƣøƼߵڼĻߣ2µĵøƼߵڼҩĻߣǹȥܹơ31Ч3ﵽCRȫ⣩10ﵽVGPRdzòֻ⣩1

  • Darzalexľ˵飺Ӧ֢עӦÿ

    ҩƷ/ƷDaratumumab/DarzalexľӦ֢ܹƵĶ෢ԹߡûơһֿCD38ĵ¡壬йɱ˻ԣ϶෢Թϸ߶ȱĿĤøCD38ӣֻͨյϸĿӦҺطӦƣ͡ġʹȺͿԡܻᵼ¿Ⱦϸƫͣܰϸ֢ϸ֢Ͱϸ֢ϸƫͣƶѪԼѪСˮƽƫͣѪС֢FDADarzal

  • ҩľЧãȫԸߣʹã

    ľҩƸ/ζ෢Թ巴Ӧʴﵽ31.1%оֲȰ׵ĵҩORRΪ18%24%˵ľҩƸ/ζ෢ԹЧڲȰͿ׵ġȫԷ棬󲿷ֻ߲ػԲӦ֣3ߵ벻ӦأֱΪH1N1Ⱦ׼Էף಻ӦУз41.9%ģ29.7%ƶѪ28.4%ѪС٣21.6%Լϸ٣20.9%ȡ3ϵIJӦҪƶѪ1

  • ľߣ۴ľ۸ǶǮ

    ҹй෢ԹѾ԰ѪλѪҺϵͳڶλԼΪʮ֮һʮ֮ȻĿǰڶԶ෢Թ̶֪ձƫͣƵأЧϲڴľ1/2ٴоУͨԸθߵоûлܼо16mg/kgľȡ36%ЧʣORRо˴ľҪһƵĶ෢ԹߵЧЩ߰1Ʒҩ֮ǰܹƣ

  • ľעʱзӦдľ

    ״עľκμעӦķ46%ڶעΪ5%עΪ4%ڶλעûзӦ3ߡӦλʱΪ1.5Сʱ(Χ0.029.3Сʱ)ڷӦעжϵķΪ37%״ΣڶκעλʱֱΪ7.04.63.4СʱעӦd֧ܾΣѣȱ͸Ѫѹ(2%)κμ(5%)DZdzѪԣηԱף̼ѣͶġĿǰľ׼Уƶ෢ԹߡľԤƽ20182

  • ľƹʱЩã

    ٴ֤DarzalexİȫЧԡһٴ106߽Darzalexľƣ29%Ļߴﵽȫʧ򲿷СҸЧƽ7.4¡ڶٴ42߽Darzalexľƣ36%Ļߴﵽȫʧ򲿷СEQUULEUS (MMY1001)оݱ߽ܴľ16/ǧˣPomalystȰ͵ƺ󣬻ߵIJֻΪ28%ȫΪ6%ϸȫΪ8%λʱ1£λ

  • ƹҩľDarzalexڹСÿ

    ľDaratumumabǿ˾Ϊ׸еƶ෢Թĵ¡ҩƷDarzalexһIgG1˵¡壨mAbͨCD38ƱCD38ϸֱͨFc鵼ĽյͨϸԣCDC߽鵼ϸѽ⣬ϸ鵼ϸԣADCCͿϸãADCPľܽ͹ԴϸCD38+MDSCsTϸCD38+TregBϸCD38+BregӼУCD38ѪϸϱĿĤǵף48kDa

  • ľҩӦ֢ʹעľ˵顿

    ľӦ֢1ľlenalidomideDexamethasoneBortezomibDexamethasoneãһƵĶ෢Թߡ2ľPomalidomideDexamethasoneãƣlenalidomideøĶ෢Թߡ3ľҩƣƼߵڼƻ򵰰Ƽߵڼϣ󼲲չԶ෢Թߡľ100mg/5ml400mg/20mlעҺľע1

  • ľ½йƶ෢ԹЩҩ

    FDA׼ƶ෢ԹҩҪɷΪࣺ1.ߵ࣬ҪƷǶȰȰɳȰ2.øƼҪƷס׺ɳף3.࣬ҪƷдľͰ鵥4.鵰øƼ࣬ҪƷ˾5.ͳͼҩ෢Թһ׸ļȻѾǶȰԼ»ĿڷøƼɳ׿ãڶθĻߣԴδҩ󡣡ݱ20193ȳľ½

  • ҩľӦ֢Щÿҽ

    ľDaratumumabǿ˾Ϊ׸еƶ෢Թĵ¡ҩƷDarzalexһIgG1˵¡壨mAbͨCD38ƱCD38ϸֱͨFc鵼ĽյͨϸԣCDC߽鵼ϸѽ⣬ϸ鵼ϸԣADCCͿϸãADCPľܽ͹ԴϸCD38+MDSCsTϸCD38+TregBϸCD38+BregӼУCD38ѪϸϱĿĤǵף48kDa

共有110页首页上一页123456789下一页尾页
客服中心
联系方式
400-001-9763
- ѯ
ɨάѯ